Frequent allelic losses of 9p21 markers and low incidence of mutations at p16(CDKN2) gene in non-Hodgkin lymphomas of B-cell lineage

Cancer Genetics and Cytogenetics

Volumn 98, Issue 1, 1997, Pages 63-68

  Fernández Piqueras, José ^a   Santos, Javier ^a   Pérez De Castro, Ignacio ^a   Meléndez, Bárbara ^d   Martínez, Beatríz ^d   Robledo, Mercedes ^b   Rivas, Carmen ^c   Benítez, Javier ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Inst Nacional de Investig Agrarias   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 9P; CHROMOSOME BAND; CHROMOSOME SATELLITE ASSOCIATION; CLINICAL ARTICLE; EXON; GENE MUTATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALLELES; CARRIER PROTEINS; CELL LINEAGE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, SATELLITE; GENETIC MARKERS; HETEROZYGOTE; HUMANS; LYMPHOMA, B-CELL; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0343376457     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(96)00400-1     Document Type: Article

References (39)

1. Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, Nobori T, Cowan JM, Rowley JD, Diaz MO (1992): Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52:2523-2529.
2. Cheng JQ, Jhanwar JC, Lu YY, Testa JR (1993): Homozygous deletions within 9p21-22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 53:4761-4763.
3. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ (1994): Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27-32.
4. Coleman A, Fountain JW, Nobori T, Olopade OI, Robertson G, Housman DE, Lugo TG (1994): Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 54:344-348.
5. Keen AJ, Knowles MA (1994): Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9:2083-2088.
6. Brenner AJ, Aldaz CM (1995): Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 55: 2892-2895.
7. Serrano M, Hannon GJ, Beach D (1993): A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
8. Duro D, Flexor MA, Bernard O, d'Agay MF, Berger R, Larsen CJ (1994): Alterations of the putative tumor suppressor gene p16/MTS1 in human hematological malignancies. C R Acad Sci Paris/Life Sci 317:913-919.
9. INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038-4044.
10. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994): A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
11. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994): Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
12. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, Pelicci PG, Lococo F (1995): Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85:2685-2690.
13. Koduru PRK, Zariwala M, Soni R, Gong JZ, Xiong Y, Broome JD (1995): Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood 86:2900-2905.
14. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Schimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H (1995): Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86:1548-1556.
15. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436-1440.
16. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS (1995): Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893-901.
17. Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T (1995): Mutational analysis of the CDKN2 (MTS1/p16 (ink4A)) gene in primary B-cell lymphomas. Blood 86: 2724-2731.
18. Pollock PM, Pearson JV, Hayward NK (1996): Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chrom Cancer 15:77-88.
19. Hussussian CJ, Struewing J, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark Jr WH, Tucker MA, Dracopoli NC (1994): Germline p16 mutations in familial melanoma. Nature Genet 8:15-21.
20. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP (1995): Deletions of the cyclin-dependent kinase inhibitor genes p16 (INK4A) and p15 (INK4B) in non-Hodgkin's lymphomas. Blood 86:1534-1539.
21. Chaganti SR, Gaidano G, Louie DC, Dalla-Favera R, Chaganti RSK (1995): Diffuse large cell lymphomas exhibit frequent deletions in 9p21-22 and 9q31-34 regions. Genes Chromosom Cancer 12:32-36.
22. Santos, J, Pérez de Castro I, Herranz M, Pellicer A, Fernández-Piqueras J (1996): Allelic losses on chromosome 4 suggest the existence of a candidate tumor suppressor gene region of about 0,6 cM in γ-radiation induced mouse primary thymic lymphomas. Oncogene 12:669-676.
23. Lennert K, Feller AC (1990): Die Kiel Klassification. Non-Hodgkin Lymphoma. Springer Verlag, Berlin, pp. 13-21.
24. Diss TC, Peng H, Wotherspoon AC, Isaacson PG, Pan L (1993): Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J Pathol 169:291-295.
25. Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA (1991): Gene rearrangement in B-and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood 78:192-196.
26. Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Millaseau P, Marc S, Bernardi G, Lathrop M, Weissenbach J (1994): The 1993-1994 Généton human genetic linkage map. Nature Genet 7:246-339.
27. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R, Dreyling MH, Gursky S, Stadler WM, LeBeau MM, Bohlander SK (1995): Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 92:6489-6493.
28. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millaseau P, Vaysseix G, Lathrop M (1992): A second-generation linkage map of the human genome. Nature 359:794-801.
29. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FJ, Kamb A (1995): CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067.
30. Kwiatkowski DJ, Diaz MO (1992): Dinucleotide repeat polymorphism at the IFNA locus (9p22). Hum Mol Genet 1:658.
31. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA (1994): Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22-26.
32. Benitez J, Robledo M, Santon A, Santos M, Rivas C, Echezarreta G, Martinez P (1992): Correlation between cytogenetic and molecular analysis of t(14,18) in follicular lymphomas. Cancer Genet Cytogenet 59:68-72.
33. Robledo M, Benitez J, Rivas C, Martinez-Castro P (1992): Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet Cytogenet 62:208-209.
34. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervit I, Lai JL, Bauters F, Wattel E, Fenaux P (1995): p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85:657-663.
35. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL et al. (1995): Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature Genet 11:210-212.
36. Otterson GA, Khleif SN, Chen WD, Coxon AB, Kaye FJ (1995): CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16 (INK4) protein induction by 5-aza 2′ deoxycytidine. Oncogene 11:1211-1216.
37. Cheng JQ, Jhahwar JC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR (1994): p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547-5551.
38. Puig S, Ruiz A, Lázaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM, Estivill X (1995): Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet 57:395-402.
39. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JWG, Riter A, Ludwig WD, Zimmermann M, Schwaller J, Lee E, Miyoshi Y, Koeffler HP (1995): Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/ MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 86:755-760.